Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

199.57 +1.09 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Natera (NTRA) Q3 2025 Earnings Call Transcript
Natera (NTRA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22... 
Via StockStory
Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance
Natera (NTRA) Q3 2025 results beat revenue forecasts with $592.2M, driven by strong oncology test growth. The company raised its full-year 2025 guidance. 
Via Chartmill
Natera (NASDAQ:NTRA) Delivers Impressive Q3
Genetic testing company Natera (NASDAQ:NTRA). reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue... 
Via StockStory
Earnings Scheduled For November 6, 2025
 
Via Benzinga
How Do Investors Really Feel About Natera?
 
Via Benzinga
Natera Reports Third Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Natera (NTRA) Reports Earnings Tomorrow: What To Expect
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings this Thursday after the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
2 Unpopular Stocks That Should Get More Attention and 1 We Ignore
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
From Natera, Inc.
Via Business Wire
Natera to Report its Third Quarter Results on November 6, 2025
From Natera, Inc.
Via Business Wire
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
From Natera, Inc.
Via Business Wire
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
A Glimpse Into The Expert Outlook On Natera Through 8 Analysts
 
Via Benzinga
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
Why Are Natera (NTRA) Shares Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.2% in the afternoon session after the company announced promising results from its phase 3 IMvigor011 clinical trial for its Signatera... 
Via StockStory
Topics Intellectual Property
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
Natera Named to Fast Company’s Next Big Things in Tech List
From Natera, Inc.
Via Business Wire
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
 
Via Benzinga
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
From Natera, Inc.
Via Business Wire
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
From Natera, Inc.
Via Business Wire
2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Retirement
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
From Natera, Inc.
Via Business Wire
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
From Natera, Inc.
Via Business Wire
2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Stocks making big moves yesterday: Acadia Healthcare, Tesla, THOR Industries, Natera, and P10
Check out the companies making headlines yesterday: 
Via StockStory
Topics Electric Vehicles
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
 
Via Benzinga
Why Natera (NTRA) Stock Is Down Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.5% in the afternoon session after Wells Fargo & Company initiated coverage on the stock with a neutral "equal weight" rating and set a... 
Via StockStory
Topics Artificial Intelligence Lawsuit
Deep Dive Into Natera Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.